Literature DB >> 8026252

RUDER--a prospective, two-year, multicenter study of risk factors for duodenal ulcer relapse during maintenance therapy with ranitidine. RUDER Study Group.

D Armstrong1, R Arnold, M Classen, M Fischer, H Goebell, W Schepp, A L Blum.   

Abstract

In a prospective study of the risk factors for duodenal ulcer relapse during maintenance (150 mg daily) ranitidine therapy, 1899 patients with chronic ulcer disease were recruited to a multicenter, German trial. Healing of all ulcers was confirmed endoscopically; endoscopy was also obligatory after one and two years or if the patients presented in the interim with symptoms of ulcer relapse. By the end of the first year, 247 patients had experienced at least one relapse and, by the end of the second year, 432 patients had relapsed at least once. The crude one- and two-year relapse rates were 13.0% (95% CI 11.5-14.5) and 22.7% (20.9-24.6%), respectively. Univariate analysis indicated that all seven prospectively defined risk factors were associated with an increased two-year relapse rate; of these, duodenal erosions distant from the healed ulcer [odds ratio (95% CI): 2.23 (1.59-3.15); P < 0.0001], smoking, past or present [1.46 (1.12-1.90); P = 0.0050], psychological stress [1.38 (1.09-1.74); P = 0.0085], heavy physical labor [1.45 (1.06-1.98); P = 0.0219], and absence of NSAID intake [1.54 (1.01-2.29); P = 0.0464] were independent risk factors on stepwise logistic regression analysis, whereas persistent symptoms at healing [1.29 (1.03-1.62), P = 0.0310] and frequent prior relapses [1.45 (1.01-2.04); P = 0.0454] were not. Multiple relapses in 107 patients [5.63% (4.60-6.67%)] were associated with duodenal erosions, smoking, stress, and heavy physical labor.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8026252     DOI: 10.1007/bf02088044

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

1.  Gastric basal secretion during exercise and restitution in patients with chronic duodenal ulcer.

Authors:  K Markiewicz; M Cholewa; M Lukin
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1979-04

2.  Smoking impairs therapeutic gastric inhibition.

Authors:  E J Boyd; J A Wilson; K G Wormsley
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

3.  The effect of stressful life situations on the healing of duodenal ulceration.

Authors:  J B Mason; M G Moshal; V Naidoo; L Schlemmer
Journal:  S Afr Med J       Date:  1981-11-07

4.  Disturbed gastroduodenal motility in patients with active and healed duodenal ulceration.

Authors:  D D Kerrigan; N W Read; L A Houghton; M E Taylor; A G Johnson
Journal:  Gastroenterology       Date:  1991-04       Impact factor: 22.682

5.  Cimetidine, cigarette smoking, and recurrence of duodenal ulcer.

Authors:  S Sontag; D Y Graham; A Belsito; J Weiss; A Farley; R Grunt; N Cohen; D Kinnear; W Davis; A Archambault
Journal:  N Engl J Med       Date:  1984-09-13       Impact factor: 91.245

6.  Prognosis of chronic duodenal ulcer: a prospective study of the effects of demographic and environmental factors and ulcer healing.

Authors:  R W Nasiry; J H McIntosh; K Byth; D W Piper
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

7.  Stressful life events, acid hypersecretion, and ulcer disease.

Authors:  M N Peters; C T Richardson
Journal:  Gastroenterology       Date:  1983-01       Impact factor: 22.682

8.  Maintenance treatment with cimetidine in peptic ulcer disease for up to 4 years.

Authors:  A Walan; G Bianchi-Porro; E Hentschel; K D Bardhan; M Delattre
Journal:  Scand J Gastroenterol       Date:  1987-05       Impact factor: 2.423

9.  Predictors of duodenal ulcer healing and relapse.

Authors:  A Sonnenberg; S A Müller-Lissner; E Vogel; P Schmid; J J Gonvers; P Peter; G Strohmeyer; A L Blum
Journal:  Gastroenterology       Date:  1981-12       Impact factor: 22.682

10.  A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer.

Authors:  G M Van Deventer; J D Elashoff; T J Reedy; D Schneidman; J H Walsh
Journal:  N Engl J Med       Date:  1989-04-27       Impact factor: 91.245

View more
  4 in total

1.  Distinctive aspects of peptic ulcer disease, Dieulafoy's lesion, and Mallory-Weiss syndrome in patients with advanced alcoholic liver disease or cirrhosis.

Authors:  Borko Nojkov; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 2.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

3.  The economic and quality-of-life benefits of Helicobacter pylori eradication in chronic duodenal ulcer disease--a community-based study.

Authors:  P S Phull; S D Ryder; D Halliday; A B Price; A J Levi; M R Jacyna
Journal:  Postgrad Med J       Date:  1995-07       Impact factor: 2.401

Review 4.  Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.

Authors:  K D Bardhan
Journal:  Yale J Biol Med       Date:  1996 May-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.